As diabetes and obesity heightened individuals’ risk for severe COVID-19, the pandemic placed an outsized spotlight on these diseases over the last two years. We’ve identified four drivers that are reshaping the delivery of care for patients with diabetes and obesity.

Download the report with strategic insights on the drivers below:

Soaring costs have spurred multi-stakeholder initiatives aimed at lowering U.S. insulin costs for consumers.

A growing range of treatments have attracted attention, but stakeholders require more evidence before supporting widespread use.

The U.S.’s fragmented and ineffective prevention efforts are pushing private industry stakeholders to take the reins in diabetes and obesity prevention.

In the wake of COVID-19, health leaders are reckoning with and responding to worsening disparities in diabetes and obesity among certain populations.